Literature DB >> 16108840

Relationship of non-alcoholic hepatic steatosis to cortisol secretion in diet-controlled Type 2 diabetic patients.

G Targher1, L Bertolini, G Zoppini, L Zenari, G Falezza.   

Abstract

AIMS: To examine the association of non-alcoholic hepatic steatosis (HS) with the activity of the hypothalamo-pituitary-adrenal (HPA) axis in Type 2 diabetic individuals.
METHODS: The activity of the HPA axis, as measured by 24-h urinary free cortisol (UFC) excretion and serum cortisol levels after 1.0 mg dexamethasone, was measured in 40 diet-controlled, predominantly overweight, Type 2 diabetic patients with non-alcoholic HS and in 40 diabetic patients without HS who were comparable for age, sex and body mass index (BMI).
RESULTS: Subjects with non-alcoholic HS had significantly higher 24-h UFC excretion (191 +/- 4 vs. 102 +/- 3 nmol/24 h; P < 0.001) and post-dexamethasone cortisol concentrations (29.1 +/- 2 vs. 14.4 +/- 1 nmol/l; P < 0.001) than those without HS. Patients with HS had significantly higher values for HOMA insulin resistance score, plasma triglycerides and liver enzymes. Age, sex, BMI, waist-hip ratio (WHR), diabetes duration, HbA1c, LDL-cholesterol and blood pressure values were not different between the groups. The differences in urinary and serum cortisol concentrations between the groups remained significant after adjustment for age, sex, BMI, WHR, HOMA insulin resistance score, plasma triglycerides, HbA1c and liver enzymes. In multiple logistic regression analyses, 24-h UFC or serum cortisol concentrations (P < 0.05 and P = 0.02, respectively), along with age and HOMA insulin resistance, predicted the presence of HS, independently of potential confounders.
CONCLUSIONS: These results demonstrate that non-alcoholic HS is closely associated with a subtle, chronic overactivity of the HPA axis in diet-controlled Type 2 diabetic individuals.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16108840     DOI: 10.1111/j.1464-5491.2005.01583.x

Source DB:  PubMed          Journal:  Diabet Med        ISSN: 0742-3071            Impact factor:   4.359


  6 in total

Review 1.  Hypothalamus-pituitary-adrenal Axis in Glucolipid metabolic disorders.

Authors:  Yanduan Lin; Ziwei Zhang; Siyu Wang; Jinyan Cai; Jiao Guo
Journal:  Rev Endocr Metab Disord       Date:  2020-09-05       Impact factor: 6.514

Review 2.  Mechanisms of glucocorticoid-induced insulin resistance: focus on adipose tissue function and lipid metabolism.

Authors:  Eliza B Geer; Julie Islam; Christoph Buettner
Journal:  Endocrinol Metab Clin North Am       Date:  2014-03       Impact factor: 4.741

3.  The impact of cortisol in steatotic and non-steatotic liver surgery.

Authors:  María Eugenia Cornide-Petronio; Esther Bujaldon; Mariana Mendes-Braz; Cindy G Avalos de León; Mónica B Jiménez-Castro; Ana I Álvarez-Mercado; Jordi Gracia-Sancho; Juan Rodés; Carmen Peralta
Journal:  J Cell Mol Med       Date:  2017-04-04       Impact factor: 5.310

4.  NAFLD Aggravates Septic Shock Due to Inadequate Adrenal Response and 11β-HSDs Dysregulation in Rats.

Authors:  Hui-Chun Huang; Ming-Hung Tsai; Fa-Yauh Lee; Te-Yueh Lin; Ching-Chih Chang; Chiao-Lin Chuang; Shao-Jung Hsu; Ming-Chih Hou; Yi-Hsiang Huang
Journal:  Pharmaceutics       Date:  2020-04-28       Impact factor: 6.321

5.  Cortisol clearance and associations with insulin sensitivity, body fat and fatty liver in middle-aged men.

Authors:  H B Holt; S H Wild; A D Postle; J Zhang; G Koster; M Umpleby; F Shojaee-Moradie; K Dewbury; P J Wood; D I Phillips; C D Byrne
Journal:  Diabetologia       Date:  2007-03-17       Impact factor: 10.122

6.  Effects of Mifepristone on Nonalcoholic Fatty Liver Disease in a Patient with a Cortisol-Secreting Adrenal Adenoma.

Authors:  Enzo Ragucci; Dat Nguyen; Michele Lamerson; Andreas G Moraitis
Journal:  Case Rep Endocrinol       Date:  2017-11-19
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.